Novel Bispecific Antibody Active in Recurrent/Metastatic Head and Neck Cancer
ORLANDO -- More than a third of patients with previously treated head and neck cancer responded to a novel bispecific antibody,…
Browsing Tag
RecurrentMetastatic
Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim…
Early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in the 2mg/kg and RP2D 4mg/kg…